No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 661 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR New Year’s Wishes 2016 December 29, 2022 Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... October 19, 2021 Young Boy Wears Shirt That Says ‘I Will Be Your Friend’... August 12, 2019 When Cancer Isn’t Your Only Challenge: How I Learned to Cope March 24, 2022 Load more HOT NEWS Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD... Will Ponsegromab Be a Game Changer for Cancer Cachexia? Coming together for Zynlonta Young Woman Considers Service Dog A Crucial Ally In Her Battle...
